8 assets in Corneal Disorder

Therapeutic assets addressing Corneal Disorder, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Belantamab Mafodotin Corneal Disorder	Hellenic Society of Hematology	P1/2	CC (47)
Daratumumab Corneal Disorder	Hellenic Society of Hematology	P1/2	CC (47)
Dexasone Corneal Disorder	Hellenic Society of Hematology	P1/2	CC (47)
Lenalidomide Corneal Disorder	Hellenic Society of Hematology	P1/2	CC (47)
Pomalidomide Corneal Disorder	Hellenic Society of Hematology	P1/2	CC (47)
Nirogacestat Corneal Disorder	Hellenic Society of Hematology	P1/2	CC (45)
Cenegermin-Bkbj Corneal Disorder	Tufts Medical Center	P1	CC (43)
Human Cord Blood Plasma Corneal Disorder	Singapore Eye Research Institute	N/A	D (30)